Deal Announcement 10/14: Pharma & MedTech

The Deal

PwC won the sell-side mandate thanks to the long-standing excellent relationship with Pfizer Inc., for which we have been carrying out a series of divestitures of pharmaceutical manufacturing sites throughout Europe in recent years.

PwC ran a highly competitive process involving both national and international financial and strategic bidders. R-Pharm eventually prevailed as the final bidder after intensive negotiations with Pfizer, for which Illertissen will continue to manufacture a series of products for a defined period.

Pfizer Inc.

Founded in 1849, Pfizer Inc. is a multinational pharmaceutical conglomerate headquartered in New York, USA, with revenues of ~USD 50bn in 2013. Its product portfolio includes human biologic and small molecule medicines and vaccines as well as a wide range of consumer products.

Illertissen site

The Illertissen site was founded in the 1860s and had been acquired by Pfizer in 1971. The state-of-the-art production site employs nearly 400 professionals. It is leading in high containment manufacturing and equipped with highly automated packaging operations. It is specialized in oral solid dosage forms and equipped to deal with complex SKU profiles and large batch sizes.

R-Pharm

Founded in 2001 in Moscow, R-Pharm is a leading Russian pharmaceutical enterprise employing 2,800 professionals in 41 branches across Russian and the CIS countries. R-Pharm realized a turn-over of USD 1,5bn in 2013. Its services portfolio includes the manufacturing of finished drugs and APIs, R&D activities and the cooperation with major international pharmaceutical companies and universities in the field of drug development and combined clinical trials.

PwC

The global PricewaterhouseCoopers network is a worldwide association of independent auditing and consulting companies which together employ more than 181,000 employees in 158 countries. Our global network comprises nearly 1,000 M&A professionals all over the world, realizing approx. 300 successful transactions per year. We specialize in a wide range of independent M&A services including advice on acquisitions and disposals, mergers, public takeovers, privatizations as well as structured financing.

PwC employs nearly 1.000 M&A professionals all over the world, advising approximately 300 successful transactions per year. We provide a wide range of independent M&A services including advice on acquisitions and disposals, mergers, public takeovers, privatizations as well as structured financing.

A joint team of PwC M&A UK and Germany acted as M&A advisor to Pfizer Inc. during the sales process of its Illertissen site. The following PwC M&A team members were involved for Pfizer Inc.:

PwC UK:
Paul Mankin (Partner), Gareth Marshall (Assistant Director), Simon John (Assistant Director), Alex Marsh (Manager).

PwC GER:
Alexander von Friesen (Partner), Alexander Wenzel (Senior Manager), Felix Huber (Senior Consultant).